Stephen A. Sherwin net worth and biography

Stephen Sherwin Biography and Net Worth

Director of Biogen

Stephen A. Sherwin, M.D., joined our Board of Directors in 2010. Dr. Sherwin is a member of our Audit Committee. Dr. Sherwin currently divides his time between advisory work in the life science industry and patient care and teaching in his specialty of medical oncology. He is a Clinical Professor of Medicine at the University of California, San Francisco, and a volunteer Attending Physician in Hematology-Oncology at the Zuckerberg San Francisco General Hospital. Dr. Sherwin also currently serves as a venture partner with Third Rock Ventures, LLC. Dr. Sherwin previously served as the Chairman of Ceregene, Inc., a life sciences company that he co-founded, from 2001 until its acquisition by Sangamo BioSciences, Inc. in 2013. He was also co-founder and Chairman of Abgenix, Inc., an antibody company that was acquired by Amgen Inc. in 2006. From 1990 to October 2009 he served as the Chief Executive Officer of Cell Genesys, Inc., a life sciences company, and was its Chairman from 1994 until the company’s merger with BioSante Pharmaceuticals, Inc. (now ANI Pharmaceuticals, Inc.) in October 2009. Prior to that, he held various positions at Genentech, Inc., a life sciences company, most recently as Vice President, Clinical Research. Dr. Sherwin is board certified in internal medicine and medical oncology.

Dr. Sherwin is also a member of the Boards of Directors of Neurocrine Biosciences, Inc. a life sciences company.

What is Stephen A. Sherwin's net worth?: The estimated net worth of Stephen A. Sherwin is at least $2.06 million as of March 7th, 2025. Sherwin owns 11,318 shares of Biogen stock worth more than $2,059,650 as of December 5th. This net worth estimate does not reflect any other assets that Sherwin may own. Learn More about Stephen A. Sherwin's net worth.
How do I contact Stephen A. Sherwin?: The corporate mailing address for Sherwin and other Biogen executives is 225 BINNEY STREET, CAMBRIDGE MA, 02142. Biogen can also be reached via phone at (617) 679-2000 and via email at [email protected]. Learn More on Stephen A. Sherwin's contact information.
Has Stephen A. Sherwin been buying or selling shares of Biogen?: Stephen A. Sherwin has not been actively trading shares of Biogen within the last three months. Most recently, Stephen A. Sherwin sold 8,760 shares of the business's stock in a transaction on Friday, March 7th. The shares were sold at an average price of $150.02, for a transaction totalling $1,314,175.20. Following the completion of the sale, the director now directly owns 11,318 shares of the company's stock, valued at $1,697,926.36. Learn More on Stephen A. Sherwin's trading history.
Who are Biogen's active insiders?: Biogen's insider roster includes Susan Alexander (EVP), Rachid Izzar (Insider), Brian Posner (Director), Eric Rowinsky (Director), Alfred Sandrock (insider), Stephen Sherwin (Director), Stephen Sherwin (Director), Stephen Sherwin (Director), Priya Singhal (Insider), and Michel Vounatsos (CEO). Learn More on Biogen's active insiders.
Are insiders buying or selling shares of Biogen?: During the last twelve months, insiders at the biotechnology company sold shares 3 times. They sold a total of 11,500 shares worth more than $1,683,325.55. The most recent insider tranaction occured on September, 2nd when insider Priya Singhal sold 517 shares worth more than $69,045.35. Insiders at Biogen own 0.2% of the company. Learn More about insider trades at Biogen.
Information on this page was last updated on 9/2/2025.

Stephen A. Sherwin Insider Trading History at Biogen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/7/2025	Sell	8,760	$150.02	$1,314,175.20	11,318
3/11/2020	Sell	2,434	$295.22	$718,565.48	16,517
6/3/2013	Sell	12,824	$233.26	$2,991,326.24

Stephen A. Sherwin Buying and Selling Activity at Biogen

Biogen Company Overview

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $181.98

$179.27

$182.69

50 Day Range

MA: $157.91

$137.37

$181.98

2 Week Range

Now: $181.98

$110.04

$185.17

Volume

1,233,937 shs

Average Volume

1,905,301 shs

Market Capitalization

$26.70 billion

P/E Ratio

16.59

Dividend Yield

N/A

Beta

0.13